Core Viewpoint - Chuangsheng Group-B (06628) experienced a significant stock price increase of 28.27%, reaching HKD 4.9, with a trading volume of HKD 21.44 million, following the announcement of its 2025 interim results which showed a revenue decline of 40.6% year-on-year [1] Financial Performance - The company reported a revenue of HKD 2.711 million for the 2025 interim period, a decrease of 40.6% compared to the previous year [1] - The net loss for the period was approximately HKD 110 million, which represents a 17.9% reduction year-on-year [1] - Earnings per share (EPS) showed a loss of HKD 0.27 [1] Clinical Developments - Chuangsheng Group has made significant breakthroughs in research and clinical trials, particularly with TST001 in combination with PD1/CAPOX for first-line treatment of gastric cancer, achieving a median overall survival (mOS) of 20.4 months among 82 enrolled patients [1] - In a subgroup of 26 patients with high expression of CLDN18.2, the mOS was 21.7 months, with a median progression-free survival (mPFS) of 16.6 months and a confirmed objective response rate (cORR) of 68%, with a median duration of response (mDoR) of 16.5 months [1] Future Clinical Trials - Following recent performance meetings, the company plans to initiate a global Phase III clinical trial for TST001 targeting gastric and gastroesophageal cancers upon receiving regulatory approval [2] - The osteoporosis drug Blosozumab (TST002) has entered Phase II clinical trials in China, showing positive early results [2] - The company is also advancing early clinical progress on innovative ADC and bispecific antibody drugs targeting tumors and autoimmune diseases [2]
港股异动 | 创胜集团-B(06628)拉升逾28% 中期净亏损同比收窄17.9% TST001研究数据首次亮相ASCO